MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

SR-3306

CAS No. : 1128096-91-2

MCE 站：SR-3306

产品活性：SR-3306 是一种有效的可渗透脑的选择性 JNK 抑制剂。

研究领域：MAPK/ERK Pathway

作用靶点：JNK

In Vitro: The effect of SR-3306 or Tat-Sab on cell viability in response to oxidative stress is measured by an MTT assay. H9c2 cells treated with 100 μM H₂O₂/FeSO₄ are ~40% viable, whereas the addition of 500 nM SR-3306 or 500 nM SR3562 to cells treated with 100 μM H₂O₂/FeSO₄ increases viability to ~90%, and the addition of 10 μM Tat-Sab peptide to cells treated with 100 μM H₂O₂/FeSO₄ increases viability to ~70% compared with 98% viability in untreated cells. Similar results are found for primary human cardiomyocytes .

In Vivo: Administration of SR-3306 [10 mg/kg/day (s.c.) for 14 days] increases the number of tyrosine hydroxylase immunoreactive (TH⁺) neurons in the SNpc by 6-fold and reduces the loss of the TH⁺ terminals in the striatum relative to the corresponding side of 6-OHDA-lesioned rats that receive only vehicle (p<0.05). In addition, SR-3306 [10 mg/kg/day (s.c.) for 14 days] decreases d-amphetamine-induced circling by 87% compared to 6-hydroxydopamine (6-OHDA)-lesioned animals given vehicle. Steady-state brain levels of SR-3306 at day 14 are 347 nM, which is approximately 2-fold higher than the cell-based IC₅₀ for this compound. Finally, immunohistochemical staining for phospho-c-jun (p-c-jun) reveals that SR-3306 [10 mg/kg/day (s.c.) for 14 days] produces a 2.3-fold reduction of the number of immunoreactive neurons in the substantia nigra pars compacta (SNpc) relative to vehicle treated rats. In lean mice, intraperitoneal (i.p.) or intracerebroventricular (i.c.v.) administration of SR-3306 reduces food intake and body weight. Moreover, i.p. and i.c.v. administrations of SR11935 exert similar anorectic effects as SR3306, which suggests JNK2 or JNK3 mediates aspect of the anorectic effect by pan-JNK inhibition. Furthermore, daily i.p. injection of SR-3306 (7 days) prevents the increases in food intake and weight gain in lean mice upon high-fat diet feeding, and this injection paradigm reduced high-fat intake and obesity in diet-induced obese (DIO) mice.

相关产品：Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  MAPK Compound Library  |  CNS-Penetrant Compound Library  |  Anti-Aging Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  SP600125  |  Anisomycin  |  Astragaloside IV  |  Guggulsterone  |  Tomatidine  |  Urolithin B  |  AS601245  |  Polyphyllin I  |  DB07268  |  Ginsenoside Re  |  SU3327  |  Isovitexin  |  Loureirin B  |  IQ-1S free acid  |  TCS JNK 5a  |  L-JNKI-1  |  IQ-3  |  Juglanin  |  (-)-Zuonin A  |  Actein  |  Esculentoside H  |  Sesamolin  |  (E)-Osmundacetone  |  AEG3482  |  JIP-1(153-163)  |  Muramyl dipeptide  |  OVA-E1 peptide  |  OVA-E1 peptide TFA

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。